Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF AUGUST 09, 2024 SAM #8291
SOLICITATION NOTICE

B -- cGMP Mitragynine HCl Supplemental Stability & Analytical Activities

Notice Date

8/7/2024 1:07:49 PM
 

Notice Type

Combined Synopsis/Solicitation
 

NAICS

541380 — Testing Laboratories
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

75N95024Q00480
 

Response Due

8/15/2024 9:00:00 AM
 

Archive Date

08/30/2024
 

Point of Contact

Sarah Adan, Phone: 3014805422
 

E-Mail Address

sarah.adan@nih.gov
(sarah.adan@nih.gov)
 

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number is 75N95024Q00480 and the solicitation is issued as a request for quotation (RFQ). �� � This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures; �and FAR Part 12�Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). � The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Curia Global, Inc., 26 Corporate Circle Albany, New York 12203 for cGMP Mitragynine HCl Supplemental Stability & Analytical Activities. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). The Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS) is conducting a preclinical development of Mitragynine (MG) to support its clinical evaluation, as part of the Helping to End Addiction Long-term initiative (HEAL). The Contractor shall provide long term stability studies on two cGMP batches of Mitragynine HCl and requalify cGMP reference standard of Mitragynine HCl annually for up to 3 years. See Attachment 1 - Statement of Work.
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/a2b5470efb094112bde07eeb592d9a8b/view)
 

Place of Performance

Address: Albany, NY 12203, USA

Zip Code: 12203

Country: USA
 

Record

SN07159822-F 20240809/240807230115 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |